Sandoz Gains Rights To Two US Injectables

Further Signal Of Intent For US Sterile Injectables Strategy

With the $1bn deal to transfer its US dermatology and orals solids operations to Aurobindo still awaiting completion, Sandoz is expanding its portfolio of sterile injectables - a key area of focus for the company - by acquiring the rights to two products from BE Pharmaceuticals.

Syringes
Sandoz is focusing on complex products like sterile injectables • Source: Shutterstock

Sandoz is continuing to show its appetite for sterile injectables and hospital drugs in the US by acquiring the rights to two mature generic injectables in the market for an undisclosed fee.

From Swiss player BE Pharmaceuticals, Sandoz will acquire the rights to generics of Merck’s Cubicin (daptomycin) 500mg and Emend (fosaprepitant...

More from Deals

Alvotech Boosts Packaging Abilities With Ivers-Lee Acquisition

 
• By 

Alvotech has acquired long-time partner Ivers-Lee to expand its in-house capacity for assembly and packaging ahead of key planned biosimilar launches in 2025, strengthening operational control and supporting global growth.

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By 

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By 

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.

Bio Usawa To Market Formycon’s Lucentis Biosimilar In Sub-Saharan Africa

 

Bio Usawa’s CEO said access to advanced biologics should not be a privilege of geography or income, as it prepares to launch Formycon/Bioeq’s ranibizumab biosimilar in Africa.

More from Business

Bakers And Fishermen: How Biosimilars Manufacturers Are Bridging The Skills Gap

 
• By 

At Medicines for Europe’s annual conference in Brussels, executives from Polpharma Biologics and Gedeon Richter spoke about the challenges in finding biosimilars manufacturing staff with the right backgrounds – and how they are looking to other industries to bridge the skills gap.

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By 

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By 

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.